Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-077 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-077

Injection

Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
GMP approvals
Japan
Comments
Indication: Acute cervical spinal cord injury, targeting neuroprotection, axonal regeneration, and functional motor recovery. Clinical stage: Phase I/II placebo-controlled double-blind comparative study completed with proof of concept; Phase III multicenter, non-randomized confirmatory study using intrathecal KP-100IT completed; additional clinical studies in Japan planned. Mechanism / Target: action on c-MET receptors to promote neuronal survival, inhibit apoptosis, enhance angiogenesis, and support axonal repair and regeneration in injured spinal cord tissue. Route / form: Intrathecal injection into the cerebrospinal fluid, administered repeatedly over the early post-injury period (as in clinical trials). Differentiation: First-in-class regenerative biologic targeting multiple repair pathways in acute spinal cord injury; demonstrated safety and clinical proof of concept in early trials; holds orphan drug designation in Japan for this indication..
Manufacturer #38606

A clinical-stage biopharmaceutical firm pioneering regenerative medicines based on a human growth factor protein. It develops therapies for intractable and rare diseases — including spinal-cord injury, organ damage, and tissue scarring — with global development and commercialization ambitions.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.